[Correspondence] Edaravone for treatment of early-stage ALS – Authors' reply

We thank Jes ús Mora for allowing us to provide clarifications on our study.1 The protocol2 required all investigators to receive ALSFRS-R video training and to be certified to meet the same evaluation standards. One patient's ALSFRS-R score at cycle 2 was evaluated by an investigator who did not meet this stan dard, and this cycle 2 score was therefore excluded from analyses. Nonetheless, since the cycle 6 endpoint data were available and adequate, this exclusion did not affect our primary analysis.

Source: Lancet Neurology - September 13, 2017 Category: Neurology Authors: Makoto Akimoto, Kazue Nakamura, Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group Tags: Correspondence Source Type: research